Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation

American Journal of Clinical Nutrition

Volumn 77, Issue 5, 2003, Pages 1269-1277

  Bosy Westphal, Anja ^a   Ruschmeyer, Martina ^a   Czech, Norbert ^a   Oehler, Gerd ^b   Hinrichsen, Holger ^a   Plauth, Matthias ^c   Lotterer, Erich ^c   Fleig, Wolfgang ^c   Müller, Manfred James ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Rehaklinik Föhrenkamp   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Folic acid; Hepatitis; Homocysteine; Liver cirrhosis; Liver transplantation; Methionine load; Vitamin B 12; Vitamin B 6

Indexed keywords

AMINO ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYANOCOBALAMIN; CYCLOSPORIN; DIURETIC AGENT; FOLIC ACID; FOLSAURE HEVERT; HOMOCYSTEINE; METHIONINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIDOXINE; TSUKUBAENOLIDE; VITAMIN B GROUP;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FATTY LIVER; FEMALE; FOLIC ACID BLOOD LEVEL; HEPATITIS; HUMAN; HYPERHOMOCYSTEINEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; POSTPRANDIAL STATE; SURGICAL TECHNIQUE; VITAMIN SUPPLEMENTATION; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; LIVER DISEASE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED;

ADULT; AREA UNDER CURVE; CASE-CONTROL STUDIES; CHRONIC DISEASE; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; METHIONINE; MIDDLE AGED; VITAMIN B 12; VITAMIN B 6;

EID: 0038474027     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/77.5.1269     Document Type: Article

References (44)

1. Horowitz JH, Rypins EP, Henderson JM, et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 1981;81:668-75.
2. Marchisini G, Buglianesi E, Fabri A, Marchi E, Zoli M, Pisi E. Defective methionine metabolism in cirrhosis: relation to severity of liver disease. Hepatology 1992;16:149-55.
3. Ben-Ari Z, Tur-Kaspa R, Baruch Y, et al. Basal and post-methionine serum homocysteine and lipoprotein abnormalities in patients with chronic liver disease. J Invest Med 2001;49:325-9.
4. Lambert D, Benhayoun S, Adjalla C, et al. Alcoholic cirrhosis and cobalamin metabolism. Digestion 1997;58:64-71.
5. Koehler KM, Baumgartner RN, Garry PJ Allen, RH, Stabler SP, Rimm EB. Association of folate intake and serum homocysteine in elderly persons according to vitamin supplementation and alcohol use. Am J Clin Nutr 2001;73:628-37.
6. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993;17:687-9.
7. 12 status. Nutrition 2000;16:296-302.
8. Look MP, Riezler R, Reichel C, et al. Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at level of gamma-cystathionase? Scand J Gastroenterol 2000;35:866-72.
9. Bosy-Westphal A, Petersen S, Hinrichsen H, Czech N, Müller MJ. Increased plasma homocysteine in liver cirrhosis. Hepatol Res 2001;20:28-38.
10. Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension 2001;38:1217-21.
11. Bernard M-C, Jubker E, Hettinger A, Lauterberg BH. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-α with and without supplementation with N-acetylcysteine. J Hepatol 1998;28:751-5.
12. Herrero JI, Quiroga J, Sangro B, et al. Hyperhomocysteinemia in liver transplant recipients: prevalence and multivariate analysis of predisposing factors. Liver Transpl 2000;6:614-8.
13. Fernandez-Miranda C, Danz M, de la Calle A, et al. Determinants of increased plasma homocysteine in 221 stable liver transplant patients. Clin Chem 2001;47:2037-40.
14. Duce AM, Ortiz P, Cabrero C, Mato JM. S-adenosyl-L-methionine synthase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988;8:65-8.
15. Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000;33:907-14.
16. 12) in patients with alcoholic liver disease. Int J Vitam Nutr Res 1982;52:266-71.
17. 12) and holotranscobalamin changes in plasma and liver tissue in alcoholics with liver disease. J Am Coll Nutr 1998;17:235-8.
18. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.
19. Bianchi G, Bugianesi E, Ronchi M, Fabri A, Zoli M, Marchesini G. Glutathione kinetics in normal man and in patients with cirrhosis. J Hepatol 1997;26:606-13.
20. Halsted CH, Villanueva J, Chandler CJ, et al. Ethanol feeding of micropigs alters methionine metabolism and increases hepatocellular apoptosis and proliferation. Hepatology 1996;23:497-505.
21. Torres L, Garcia-Trevijano ER, Rodriguez JA, et al. Induction of TIMP-1 expression in rat hepatocyte stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999;1455:12-22.
22. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Müller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997;16:43-55.
23. Pugh RNH, Murray-Lyon IM, Dowson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
24. Müller MJ. Metabolism of energy-yielding substrates in patients with liver cirrhosis. Clin Investig 1994;72:568-79.
25. Fermo I, Arcelloni C, De Vecchi E, Vigano S, Paroni R. High-performance liquid chomatographic method with fluorescence detection for the determination of total homocyst(e)ine in plasma. J Chromatogr 1992;593:171-6.
26. 6 vitamers, especially pyridoxal 5′-phosphate. J Chomatogr 1996;722:295-301.
27. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentrations. Scand J Clin Lab Invest 1996;56:41-6.
28. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to GFR in diabetes. Kidney Int 1999;55:1028-35.
29. Chanarin I. The effects of nitrous oxide on cobalamins, folates, and on related events. Crit Rev Toxicol 1982;10:179-213.
30. Dudman NPB. An alternative viewpoint of homocysteine. Lancet 1999;354:2072-4.
31. Egerton W, Silberberg JS, Cooks R, Ray C, Xie L, Dudman NPB. Plasma levels of homocyst(e)ine during the acute phase response. Am J Cardiol 1996;77:759-61.
32. Lindgren A, Brattstrom LE, Norrvig B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phase after stroke. Stroke 1995;26:795-800.
33. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter to antifolate effect. A study on psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 1989;46:510-20.
34. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia. Changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
35. Roubenoff R, Dellaripa P, Nadeau MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthr Rheum 1997;40:718-22.
36. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
37. Von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocystein(e)mia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:460-4.
38. Evans RW, Shanten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk for cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947-53.
39. 6-vitamer profile and response to a pyridoxine load in normal and cirrhotic patients. Hepatology 1986;6:464-71.
40. Mitchell D, Wagner C, Stone WJ, Wilkinson GR, Schenker S. Abnormal regulation of plasma pyridoxal 5-phosphate in patients with liver disease. Gastroenterology 1976;71:1043-9.
41. Anderson BB, O'Brien H, Griffin GE, Mollin DL. Hydrolysis of pyridoxal 5-phosphate in plasma in conditions with raised alkaline phosphatase. Gut 1980;21:192-4.
42. 6 metabolism for patients with cirrhosis. Am J Clin Nutr 1986;44:461-7.
43. Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5′-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984;86:632-6.
44. Martin-Duce AM, Ortiz P, Cabrero C, Mato JM. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988;8:65-8.